Insider · CIK 0001578200
Schenkein David P
director
Files at DNLI (Denali Therapeutics Inc.). First filing Nov 13, 2024, latest Nov 13, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $1.9M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 40Moderate | sell 310b5-1 | DNLI Denali Therapeutics Inc. | $1.9M | 59,441 | -87% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +47,165 | $18.00 | $849k | 68,661 | Nov 13, 2024 |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -27,129 | $32.09 | $871k | 41,532 | Nov 13, 2024 |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -32,312 | $32.87 | $1.1M | 9,220 | Nov 13, 2024 |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -47,165 | $0.00 | $0 | 0 | Nov 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.